Clinical trials: Estrogen Therapy
Breast Cancer
Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00084396
- Testing
- letrozole, conventional surgery
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Washington University School of Medicine
Advanced Breast Cancer
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
- Trial name
- VERITAC-2 (NCT05654623)
- Testing
- ARV-471, Fulvestrant
- Where
- 312 sites in United States, Argentina and 29 more
- Volunteers
- 624 people
- Sponsor
- Pfizer
Breast Cancer
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
The long-term objective of this research is to understand the molecular mechanisms of acquired endocrine resistance in breast cancer.
- Trial name
- NCT00993642
- Testing
- Panobinostat (LBH589)
- Where
- United States
- Sponsor
- Tulane University Health Sciences Center
Menopause
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets
- Trial name
- NCT00141570
- Testing
- esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
- Where
- 77 sites in United States
- Volunteers
- 350 people
- Sponsor
- Solvay Pharmaceuticals
Menopausal Symptoms
Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy
About one third of all women during menopausal transition have significant climacteric symptoms with considerable impact on quality of life.
- Trial name
- NCT05586724
- Testing
- Micronized progesterone in continuous combination with oral estrogen, Norethisterone acetate in continuous combination with oral estrogen
- Where
- Sweden
- Volunteers
- 520 people
- Sponsor
- Angelica Lindén Hirschberg
Breast Cancer
Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)
The aim of this study is to learn more about how physical activity and cardiorespiratory fitness are related to diabetes risk among breast cancer patients prescribed an endocrine therapy.
- Trial name
- ABIDE (NCT06830486)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Menopause, Hypertension
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure
Calcitonin, calcitonin gene-related peptides (CGRPs), adrenomedullin, and amylin belong to a unique group of peptide hormones important for the regulation of calcium balance, neurotransmission, cardiovascular homeostasis, and…
- Trial name
- NCT00133783
- Testing
- intermedin
- Where
- Taiwan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Breast Cancer, Estrogen Receptor Positive Tumor
Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients
Aim of this study is to characterize the chemical/physical and structural parameters of the skin in patients with breast cancer undergoing oncological adjuvant treatment in order to understand how to prevent and manage adverse…
- Trial name
- NCT06474988
- Testing
- Skin tests
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Estrogen Receptor-positive Breast Cancer, Fulvestrant
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer
This study is focused on the value of 18F-FES-PET in predicting the Fulvestrant efficacy in hormone receptor-positive breast cancer. The imaging agent involved in this study is 16α-[18F]-fluoro-17β-estradiol (18F-FES).
- Trial name
- PET (NCT03768479)
- Testing
- 18F-FES-PET
- Where
- China
- Volunteers
- 68 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Breast Cancer
Preoperative Estetrol in Breast Cancer
The study is designed as a single-center, randomized, double-blind, placebo-controlled study in pre- and postmenopausal women who will undergo surgery for breast cancer.
- Trial name
- NCT00464516
- Testing
- Estetrol
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Pantarhei Bioscience
Invasive Breast Cancer
Pre-Surgical Intervention for Targeted Therapies for Breast Cancer
The purpose of this study is to determine the feasibility of a short term administration of a targeted therapy (i.e., anastrozole) in women with newly diagnosed early invasive or non invasive breast cancer during the interval…
- Trial name
- NCT01004744
- Testing
- Anastrozole
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido
This study is designed to evaluate the efficacy and safety of 2 doses of the transdermal testosterone patch in naturally or surgically menopausal women with low libido who are not receiving systemic estrogen or estrogen progestin…
- Trial name
- NCT00131495
- Testing
- Testosterone (transdermal patches)
- Where
- Australia
- Volunteers
- 814 people
- Sponsor
- Warner Chilcott
Acromegaly
Estrogen Treatment in Acromegalic Women
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
- Trial name
- NCT00315107
- Testing
- Alesse
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Université de Montréal
Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
This phase II trial studies how well pembrolizumab works when given together with endocrine therapy and palbociclib in treating postmenopausal patients with newly diagnosed stage IV estrogen receptor positive breast cancer that…
- Trial name
- NCT02778685
- Testing
- Fulvestrant, Laboratory Biomarker Analysis, Letrozole
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- City of Hope Medical Center
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast…
- Conditions
- Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
- Trial name
- NCT04443348
- Testing
- Radiation Therapy Boost, Pembrolizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Laura M. Spring, MD
Breast Cancer Stage II
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in…
- Trial name
- RIBOLARIS (NCT05296746)
- Testing
- Ribociclib (neoadjuvant), Chemotherapy (adjuvant), Ribociclib (adjuvant)
- Where
- 51 sites in France, Portugal and 1 more
- Volunteers
- 1,100 people
- Sponsor
- SOLTI Breast Cancer Research Group
Genitourinary Syndrome of Menopause (GSM)
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the…
- Trial name
- NCT07038070
- Testing
- Vaginal estrogen tablet, Via Solv Wellness (Hyaluronic Acid Therapy)
- Where
- United States
- Sponsor
- NYU Langone Health
Solid Tumors, Ovarian Cancer
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT02476955
- Testing
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Aging, Menopause
Estrogen Use in Protection From Cognitive Decline
This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.
- Trial name
- NCT00097058
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Stanford University